Real World Evidence for Oritavancin Use in Gram-Positive Infections
media
posted on 2020-07-02, 08:34 authored by Mark Redell, Sandy Estrada, Thomas P. Lodise, Glenn S Tillotson, Dino Delaportas, Lauren E. Brownell, Meagan L. Adamsick, Erin K. McCreary, Joshua P. Vanderloo, Erika J. Ernst, Emily R. Jackson, Lucas T. Schulz, Brittany Helton, Ashley MacWhinnie, Sarah Brooks Minor, Kelly D. Rafferty, Steven L. Allison, Cristen Whittaker, Ethan Nhan, Joseph Reilly, Warren E. Rose, Paul R. Hutson, Nicholas W. Van Hise, Vishnu Chundi, Vishal Didwania, Michael Anderson, David McKinsey, Ingrid Roig, Akhilesh Sharma, Russell M. Petrak, Patrick J. Scoble<p></p><p><strong>Article full text</strong></p><p> </p><p>These
articles are part of a supplement to <i>Drugs – Real World Outcomes</i> titled
“Real World Evidence for Oritavancin Use in Gram-Positive Infections” wholly
funded by Melinta Therapeutics. You can find the supplement <a href="https://link.springer.com/journal/40801/7/1/suppl">here</a>.</p><p> </p><p>The
above summary slides represent the opinions of the authors. For a full list of
declarations, including funding and author disclosure statements, please see
the full texts online (see “read the peer-reviewed publication” opposite).</p><p>
</p><p>©
The authors, CC-BY-NC 2020.</p><p></p>
History
Related Materials
- 1.
- 2.
